EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB:FCSC), an autologous cellular therapeutic company focused on the development of innovative products for aesthetic, medical and scientific applications, announced that clinical trial data demonstrating the effectiveness of LAVIV™ (azficel-T) for the improvement of the appearance of moderate-to-severe nasolabial fold wrinkles (“smile lines”) was presented late Friday afternoon at the 2011 American Society of Dermatologic Surgery Annual Meeting in Washington, D.C. LAVIV is a breakthrough new treatment for “smile line” wrinkles made from a person’s own collagen producing skin cells and is the first and only personalized cell therapy approved by the FDA for aesthetic use.
